Literature DB >> 11112346

Genetic mapping of a mouse modifier gene that can prevent ALS onset.

C B Kunst1, L Messer, J Gordon, J Haines, D Patterson.   

Abstract

Mutations in the cytoplasmic Cu/Zn superoxide dismutase (SOD1) gene on human chromosome 21q22.1 cause 10-20% of familial amyotrophic lateral sclerosis (ALS) cases. The expression of the ALS phenotype in mice carrying the murine G86R SOD1 mutation is highly dependent upon the mouse genetic background. This is similar to the phenotypic variation observed in ALS patients containing identical SOD1 mutations. In the FVB/N background, mice expressing mG86R SOD1 develop an ALS phenotype at approximately 100 days. However, when these mice were bred into a mixed background of C57Bl6/129Sv, the onset of the ALS phenotype was delayed (143 days to >2 years). Using 129 polymorphic autosomal markers in a whole genome scan, we have identified a major genetic modifier locus with a maximum lod score of 5.07 on mouse chromosome 13 between D13mit36 and D13mit76. This 5- to 8-cM interval contains the spinal muscular atrophy (SMA)-associated gene Smn (survival motor neuron) and seven copies of Naip (neuronal apoptosis inhibitory protein), suggesting a potential link between SMA and ALS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112346     DOI: 10.1006/geno.2000.6379

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  16 in total

1.  A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q.

Authors:  Collette K Hand; Jawad Khoris; François Salachas; François Gros-Louis; Ana Amélia Simões Lopes; Veronique Mayeux-Portas; Carl G Brewer; Robert H Brown; Vincent Meininger; William Camu; Guy A Rouleau
Journal:  Am J Hum Genet       Date:  2001-11-09       Impact factor: 11.025

Review 2.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

3.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

4.  Copper-zinc superoxide dismutase-deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein 35-55.

Authors:  Chandirasegaran Massilamany; Arunakumar Gangaplara; Heejeong Kim; Charlotte Stanford; Govardhan Rathnaiah; David Steffen; Jaekwon Lee; Jay Reddy
Journal:  J Neuroimmunol       Date:  2013-01-05       Impact factor: 3.478

Review 5.  Proteostasis in cardiac health and disease.

Authors:  Robert H Henning; Bianca J J M Brundel
Journal:  Nat Rev Cardiol       Date:  2017-06-29       Impact factor: 32.419

Review 6.  Genetic modifiers of neurological disease.

Authors:  Jennifer A Kearney
Journal:  Curr Opin Genet Dev       Date:  2011-01-19       Impact factor: 5.578

Review 7.  A cellular perspective on conformational disease: the role of genetic background and proteostasis networks.

Authors:  Tali Gidalevitz; Elise A Kikis; Richard I Morimoto
Journal:  Curr Opin Struct Biol       Date:  2010-01-05       Impact factor: 6.809

8.  Mutant glycyl-tRNA synthetase (Gars) ameliorates SOD1(G93A) motor neuron degeneration phenotype but has little affect on Loa dynein heavy chain mutant mice.

Authors:  Gareth T Banks; Virginie Bros-Facer; Hazel P Williams; Ruth Chia; Francesca Achilli; J Barney Bryson; Linda Greensmith; Elizabeth M C Fisher
Journal:  PLoS One       Date:  2009-07-13       Impact factor: 3.240

9.  Redox modifier genes in amyotrophic lateral sclerosis in mice.

Authors:  Jennifer J Marden; Maged M Harraz; Aislinn J Williams; Kathryn Nelson; Meihui Luo; Henry Paulson; John F Engelhardt
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 10.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.